{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:02:39Z","timestamp":1789095759446,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ahjonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ahj.2016.05.014","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T20:05:01Z","timestamp":1465675501000},"page":"161-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Defining nonvalvular atrial fibrillation: A quest for clarification"],"prefix":"10.1016","volume":"178","author":[{"given":"Rapha\u00ebl P.","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Galand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Colette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Behar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Pavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Daubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2016.05.014_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"Zoni-Berisso","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ahj.2016.05.014_bb0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2016.05.014_bb0015","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.05.014_bb0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.05.014_bb0025","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.05.014_bb0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.05.014_bb0035","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation\u2014developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2016.05.014_bb0040","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2016.05.014_bb0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2016.05.014_bb0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2016.05.014_bb0055","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.113.004742","article-title":"Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation","volume":"129","author":"Martins","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.05.014_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(14)61106-5","article-title":"New oral anticoagulants in patients with atrial fibrillation - Authors'reply","volume":"384","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2016.05.014_bb0065","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/europace\/euu178","article-title":"The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey","volume":"16","author":"Molteni","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2016.05.014_bb0070","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ahj.2016.05.014_bb0075","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/eurheartj\/ehv163","article-title":"Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project","volume":"36","author":"Philippart","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2016.05.014_bb0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijcard.2009.06.051","article-title":"Relation of the severity of mitral regurgitation to thromboembolic risk in patients with atrial fibrillation","volume":"146","author":"Fukuda","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2016.05.014_bb0085","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0002-8703(98)70231-5","article-title":"Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"136","author":"Nakagami","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2016.05.014_bb0090","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2016.05.014_bb0095","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.05.014_bb0100","unstructured":"http:\/\/content.onlinejacc.org\/article.aspx?articleid=1857045."},{"key":"10.1016\/j.ahj.2016.05.014_bb0105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses","volume":"89","author":"Cannegieter","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.05.014_bb0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"Cannegieter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.05.014_bb0115","first-page":"383","article-title":"Dabigatran in patients with mechanical heart valves","volume":"370","author":"Eikelboom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.05.014_bb0120","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1161\/CIRCULATIONAHA.108.190748","volume":"118","author":"Bonow","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.05.014_bb0125","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1161\/CIR.0000000000000031","article-title":"2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Nishimura","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.05.014_bb0130","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","article-title":"Guidelines on the management of valvular heart disease (version 2012)","volume":"33","author":"Vahanian","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2016.05.014_bb0135","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2016.05.014_bb0140","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1160\/TH16-01-0007","article-title":"Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project","volume":"115","author":"Philippart","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2016.05.014_bb0145","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01868243."},{"key":"10.1016\/j.ahj.2016.05.014_bb0150","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01868243"},{"key":"10.1016\/j.ahj.2016.05.014_bb0155","unstructured":"http:\/\/circ.ahajournals.org\/content\/132\/Suppl_3\/A17277.abstract?related-urls=yes&legid=circulationaha;132\/Suppl_3\/A17277."},{"key":"10.1016\/j.ahj.2016.05.014_bb0160","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non\u2013vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2016.05.014_bb0165","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jtcvs.2011.02.011","article-title":"Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves","volume":"141","author":"McKellar","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ahj.2016.05.014_bb0170","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/08941939.2011.616256","article-title":"Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model","volume":"25","author":"Schomburg","year":"2012","journal-title":"J Invest Surg"},{"key":"10.1016\/j.ahj.2016.05.014_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2016.05.014_bb0180","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11239-011-0621-6","article-title":"Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study","volume":"32","author":"Kaeberich","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2016.05.014_bb0185","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ejcts\/ezt545","article-title":"Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model","volume":"45","author":"Greiten","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ahj.2016.05.014_bb0190","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.05.014_bb0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euv288","article-title":"Non\u2013vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial","volume":"18","author":"De Caterina","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2016.05.014_bb0200","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is 'valvular' atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316300849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316300849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T07:55:10Z","timestamp":1536652510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870316300849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":40,"alternative-id":["S0002870316300849"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2016.05.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining nonvalvular atrial fibrillation: A quest for clarification","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}